PlainRecalls
FDA Drug Low Class III Completed

NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03

Reported: April 24, 2024 Initiated: March 27, 2024 #D-0441-2024

Product Description

NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03

Reason for Recall

Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.

Details

Recalling Firm
Esperion
Units Affected
3,480 30-count bottles
Distribution
Nationwide in the USA
Location
Ann Arbor, MI

Frequently Asked Questions

What product was recalled?
NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03. Recalled by Esperion. Units affected: 3,480 30-count bottles.
Why was this product recalled?
Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 24, 2024. Severity: Low. Recall number: D-0441-2024.